Equity Overview
Price & Market Data
Price: $2.51
Daily Change: +$0.01 / 0.40%
Range: $2.37 - $2.53
Market Cap: $126,212,592
Volume: 246,843
Performance Metrics
1 Week: -2.33%
1 Month: -16.61%
3 Months: -23.71%
6 Months: -43.08%
1 Year: -45.55%
YTD: -29.10%
Company Details
Employees: 164
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. The company has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.